Hypoglycemia: The Most Common Barrier to Effective Diabetes Management

Slides:

Advertisements

Similar presentations

1 Type 1 Diabetes Mellitus Treatment. 2 Goals of T1DM Management Utilize intensive therapy aimed at near-normal BG and A1C levels Prevent diabetic ketoacidosis.

Advertisements

Diabetes Technology Update

Needle-Free Diabetes Care Josiah Riggins. Back Ground  2 Types of Diabetes  Insulin Key Hormone  Diabetes can be fatal and will be over time if there.

Continuous Glucose Monitors

---- Ping Lang Super Component of Blood Sugar Monitor 1 Term Project Description: Monitoring patients blood sugar, based on different knowledge bases,

Identify the risk factors, diagnosis and prevalence of diabetes in the United States. Describe the function of the pancreas, the intestines and liver.

Dr Zaranyika MBChB(Hons) UZ, MPH, FCP SA Department of Medicine UZ-CHS

Copyright © 2015 by the American Osteopathic Association.

Volume 64, Issue 4, Pages (October 2003)

Dr Adhya Mehta Department of Medicine

Fig. 1. Scheme of the evaluation protocol

Best offer from Medtek.  Multiple blood chemistry testing  One-step testing  Results in two minutes or less  Automatic calibration with inserted MEMo-Chip.

Type 1 Diabetes: Meters, Pumps, and Transitions to Adulthood

Diabetic Dyslipidemia in Practice

Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.

Diabetes and Risk of CV Outcomes

Lifestyle and Professional CGM

Components of a CGM record over a 3

Program Goals. Inhaled Insulin: Overcoming Past Obstacles With Advances in Understanding.

Using the AGP to Standardize Glucose Reporting

Overview of Disparities

Modern Strategies for Basal Insulin Use in T2D

Epilepsy Treatment Across the Spectrum

Utilizing New Technologies and Insulins for a Tighter Grip on PPG

Updates on Outcomes for Novel T2D Therapies

Section VIII. Ambulatory BP Measurement

How Early Should Basal Insulin Be Used in T2D Management?

Hemoglobin A1c Targets for Glycemic Controls

Best Practices in Advanced Glucose Monitoring

SGLT2 Inhibitors in the Modern Era: Why and Where?

Before and After: Patient Cases in Onychomycosis

Examining CV Effects of Basal Insulin Therapy

Updates to Managing Diabetes in the Long-Term Care Setting

Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?

Emerging Basal Insulins for Diabetes

Improving Management of Type 2 Diabetes in Hispanic/Latino Patients

A: Percentage of type 1 diabetic and type 2 diabetic patients with asymptomatic hypoglycemias detected by the CGMS. B: Daily distribution of asymptomatic.

Integrated Diabetes Care: How Can We Make the Best Use of New Technology?

Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA

George Dailey, MD Mayo Clinic Proceedings

EXAMINE Study: Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome.

The Research Question Does self monitoring of blood glucose (SMBG) in patients with non-insulin treated type 2 diabetes improve glycemia or quality of.

Simplifying Insulin Delivery for Better Patient Outcomes in T2D

The Primary Care Guide to New CGM Devices and the AGP

Novel Approaches to T1D Management

Glucose Monitoring: An Evolving Landscape

Fig. 1. Glycemic variability in three hypothetical patients who have the same mean blood glucose concentration. Patient B has relatively small variations.

Goals. Weight Management Goals and Approaches in Patients With Type 2 Diabetes.

Aspirin and Cardioprevention in 2018

Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?

Modern Advances in Glucose Monitoring

Younger Patients With Type 1 Diabetes: Can We Optimize Their Insulin Therapy?

Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.

Dual SGLT1/SGLT2 Inhibition in T1D

Advancements in Glucose Monitoring

Insulin in Diabetes Management: Effective Patient Selection Is Key

Liraglutide Shows CV Benefit: Clinical Perspectives on the LEADER Trial

Pharmaceutical care planning 2 Ola Ali Nassr

NP and PA Expert Exchange:

Volume 64, Issue 4, Pages (October 2003)

Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Antiarrhythmic Drugs in AF

Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.

Representative study BG profiles from the forearm and the fingertip of six patients with diabetes. Representative study BG profiles from the forearm and.

The continuous line represents the sensor glucose values.

Emerging Basal Insulins for Diabetes

Based on personal experience, conversations with experts, and a literature review, this is a partial list of factors that can affect blood glucose. Based.

Fresh perspectives ON BASAL Insulins in diabetes care

Presentation transcript:

Expanding the Pharmacist's Clinical Involvement With CGM Data Interpretation

Hypoglycemia: The Most Common Barrier to Effective Diabetes Management

Methods to Monitor Blood Glucose

CGM: 3 Components

Pharmacists Can Help Patients Use And Understand CGM Technology

Updates on CGM Devices

The Glucose Pattern Summary and the Ambulatory Glucose Profile (AGP)

Using the Ambulatory Glucose Profile (AGP) to Interpret Glucose Data

Examine the Daily Curves for Patterns

Identifying the Risk for Hypoglycemia

Closing Remarks

Abbreviations